



ASIAPHARM Group Ltd

Press Release

ASIAPHARM PLEDGES RMB 1.84 MILLION TO SICHUAN EARTHQUAKE RELIEF EFFORTS

Singapore, 20 May 2008 – Singapore Exchange Main Board-listed AsiaPharm Group Ltd. (“AsiaPharm” or “the Group” or “亚洲药业集团有限公司”), a leading specialty pharmaceutical group in the People’s Republic of China (“PRC”) announced today that it has donated medical supplies and monies from the Group and its staff, totaling approximately RMB 1.84 Million to the Red Cross Society of China, to aid emergency relief efforts in Sichuan, China, following an earthquake that hit the province on Monday, 12 May 2008.

With rising shortages of basic necessities and medical supplies hampering relief efforts, Asiapharm’s latest pledge to the Red Cross Society includes drugs with market value of RMB 1.02 million targeted at treating medical condition of survivors of the quake Such as Sailimai, which is used in the treatment of acute diarrhea and Olai, which is an anti-inflammatory drug with pain-relief properties. The Group together with its subsidiaries – namely Shandong Luye Pharmaceuticals Co., Ltd., Nanjing Kanghai Pharmaceuticals Co., Ltd., Nanjing Sike Pharmaceuticals Co., Ltd. and WBL Peking University Biotech Co. Ltd – and staff have also made donations of approximately RMB 817,000 to support relief activities in the affected areas.

“Asiapharm Group would like to express its deepest sympathies and condolences to the victims of the recent earthquake in Sichuan Province. In the face of this disaster, we sincerely hope that our donations will aid the ongoing humanitarian efforts in Wenchuan County, which is the epicenter of the quake. We also wish to extend our deep appreciation for the numerous aid and relief workers who are at this moment doing everything they can to rescue the victims of this unfortunate incident,” said Mr Liu Dianbo, Executive Chairman of AsiaPharm.

About AsiaPharm Group Ltd.

Established in 1994, we are today a leading specialty pharmaceutical group in the People's Republic of China ("PRC") focusing on the research and development, production and sale of natural drugs and drug delivery systems. Fully equipped, integrated and GMP-certified, our ultra-modern facilities in Yantai and Nanjing enables us to carry out all aspects of pre-clinical evaluation – from pharmaceutical to pharmacology research, drug safety evaluation and clinical trials – as well as full production of our natural and new DDS technology drugs. AsiaPharm currently employs approximately 140 researchers and has close collaborative relationships with renowned universities and research institutions around the globe to complement its R&D efforts, enabling AsiaPharm to stay at the forefront of specialty pharmaceutical developments. To reach our customers, we have established an extensive distribution network of 35 sales support offices, covering 30 provinces, municipals, and autonomous regions, reaching approximately 3500 hospitals. This is further supported by 500 sales and marketing personnel. In line with our international expansion strategy, AsiaPharm has established a market presence in Vietnam, Pakistan, Korea, Malaysia and Singapore.

Issued on behalf of AsiaPharm Group Ltd. by WeR1 Consultants Pte Ltd

Media Contact Info

WeR1 Consultants Pte Ltd

29 Scotts Road,

Singapore 228224

Tel : (65) 6737 4844

Fax: (65) 6737 4944

Lai Kwok Kim, laikkin@wer1.net or Yim Jeng Yuh, yimjy@wer1.net